A Trial of Centanafadine Efficacy, Safety, and Tolerability in Adult Subjects With Binge Eating Disorder

PHASE2CompletedINTERVENTIONAL
Enrollment

147

Participants

Timeline

Start Date

December 22, 2021

Primary Completion Date

August 19, 2022

Study Completion Date

August 19, 2022

Conditions
Binge-Eating Disorder
Interventions
DRUG

Centanafadine

Sustained-release oral tablets

DRUG

Placebo

Oral tablets

Trial Locations (25)

10036

Manhattan Behavioral Medicine, New York

10128

Medical Research Network, LLC, New York

10312

Richmond Behavioral Associates, Staten Island

30030

iResearch Atlanta, Decatur

30060

Psych Atlanta, PC, Marietta

32256

Clinical Neuroscience Solutions - Jacksonville, Jacksonville

33176

Miami Dade Medical Research Institute, Miami

38119

Clinical Neuroscience Solutions, Inc., Memphis

45040

Craig and Frances Linder Center of Hope, Mason

45417

Midwest Clinical Research Center, Dayton

63304

St. Charles Psychiatric Associates & Midwest Research Group, Weldon Spring

66208

Collective Medical Research, Prairie Village

66211

Psychiatric Associates, Overland Park

75231

FutureSearch Trials - Dallas, Dallas

78737

Psychiatry + Psychotherapy Partners Austin, Austin

80209

Mountain View Clinical Research, LLC, Denver

85016

NoesisPharma, LLC, Phoenix

90210

Southern California Research LLC, Beverly Hills

91316

Pharmacology Research Institute - San Fernando Valley, Encino

91786

Pacific Clinical Research Management Group LLC, Upland

92845

Collaborative Neuroscience Research, LLC, Garden Grove

02131

Boston Clinical Trials, Boston

03801

ActivMed Practices and Research - Portsmouth, Portsmouth

08002

Center for Emotional Fitness, Cherry Hill

08540

Princeton Medical Institute, Princeton

All Listed Sponsors
lead

Otsuka Pharmaceutical Development & Commercialization, Inc.

INDUSTRY

NCT05113953 - A Trial of Centanafadine Efficacy, Safety, and Tolerability in Adult Subjects With Binge Eating Disorder | Biotech Hunter | Biotech Hunter